Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. (Nasdaq Capital Market: OTLK) is a biopharmaceutical company focused on developing and commercializing ophthalmic therapeutics. The company's website is www.outlooktherapeutics.com.

The company's primary product is ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab, a humanized anti-VEGF monoclonal antibody that inhibits vascular endothelial growth factor and associated angiogenic activity. LYTENAVA represents the first and only approved ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration, or wet AMD. The product received marketing authorization from the European Commission in May 2024 and from the UK Medicines and Healthcare products Regulatory Agency in July 2024, with direct commercialization launched in Germany and the UK in June 2025. The company is pursuing FDA approval in the United States, with a Prescription Drug User Fee Act goal date of December 31, 2025 for a regulatory decision.

Outlook is developing LYTENAVA for additional retinal indications including diabetic macular edema and branch retinal vein occlusion. The company has completed four clinical trials in its NORSE program, with NORSE TWO demonstrating that LYTENAVA met primary and key secondary efficacy endpoints compared to ranibizumab. NORSE EIGHT, a subsequent trial required by the FDA, showed vision improvement and favorable safety but did not meet its pre-specified non-inferiority endpoint at week eight, though data at week twelve demonstrated non-inferiority.

The company operates through a capital-efficient model, outsourcing manufacturing and clinical trial operations to third-party providers. Outlook has entered into a strategic collaboration agreement with Cencora for distribution and commercialization support in the EU and UK. The company also maintains a joint venture with Syntone for development and commercialization rights in the greater China market, including Hong Kong, Taiwan, and Macau.

Outlook addresses a significant market opportunity, with the global anti-VEGF retina market estimated at approximately sixteen billion dollars annually. The company targets the substantial off-label bevacizumab market, where approximately 2.8 million injections occur annually in Europe and 2.7 million in the United States, positioning LYTENAVA as a compliant, regulated alternative to compounded formulations.